Wiskott-Aldrich syndrome (WAS) — disease overview, therapies, and what Waskyra changes
1) What is Wiskott-Aldrich syndrome (WAS) and how it is caused WAS is an X-linked primary immunodeficiency that typically affects males and is caused by mutations in the WAS gene, which encodes the Wiskott-Aldrich syndrome protein (WASp). WASp is expressed in hematopoietic cells and is essential for reorganization of the actin cytoskeleton during immune-cell activation, […]
A Deep Dive into the FDA Approval of NDA 215244 (s000): What We Know, What It Means, and What Comes Next
Introduction The issuance of label 215244s000 marks the formal U.S. FDA approval of a new therapeutic agent (or new indication) under NDA 215,244. While publicly available summaries are scarce, the full prescribing label document offers a wealth of technical information that can be unpacked to understand the drug’s mechanism, safety/efficacy profile, clinical trial evidence, potential […]
RYBREVANT (amivantamab-vmjw) 2025 Label: What Changed, Why It Matters, and How to Apply It in Practice
Bottom line: In early 2025 the RYBREVANT label tightened safety language (notably infusion-related reactions, anaphylaxis placement, and venous thromboembolism management with lazertinib) and clarified dosing/administration details. Later in 2025, FDA accepted a supplement to update overall survival results from MARIPOSA, which will flow into Clinical Studies once the updated PI posts. Together, these moves round […]
Breaking News: FDA Expands IZERVAY™ Label for Long-Term Use in Geographic Atrophy Management
1. What’s New? The U.S. Food and Drug Administration has approved an expanded prescribing label for IZERVAY™, enabling unlimited duration dosing in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) Astellas Pharma US, Inc. | News Room. Previously, treatment duration was capped at 12 months. 2. Clinical Evidence Behind the Expansion This […]
Data required to be submitted by an applicant for conduct of clinical trial of an approved new drug with new claims, namely, new indication or new dosage form or new route of administration or new strength
Data required to be submitted by an applicant forconduct of clinical trial of an approved new drug with new claims, namely, new indication or new dosage form or new route of administration or new strength
Requirements for drug approval with new claims
In case a drug already approved by the Central Licencing Authority for certain claims, which is now proposed to be clinically tried or marketed with modified or new claims, namely, indications, dosage, dosage form (including sustained release dosage form) and route of administration or novel drug delivery system (NDDS), the requirements of data and information […]